Heidi Savage - Concepedia

Concepedia

Author

Heidi Savage

Dana-Farber Cancer Institute

Also Known As

H Savage, Heidi M Savage, Heidi M. Savage, Heidi Savage, Savage, H.

132

Publications

2.2K

Citations

16

H-Index

29

Concepts

All Affiliations

Dana-Farber Cancer Institute Texas Oncology Queen Mary University of London Massachusetts General Hospital Vall d'Hebron Institute of Oncology

HS

About

Heidi Savage is an author at Dana-Farber Cancer Institute specializing in breast cancer, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	215
2	Engineering	1	1	69
3	Cell Biology	1	1	69
4	Immunology	1	1	86
5	Obstetrics	1	1	60

Heidi Savage

×

17

Publications

2.2K

Citations

16

H-Index

	Year	Citations
<i>In vivo</i> Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models Klaus P. Hoeflich, Carol O’Brien, Zachary Boyd, Clinical Cancer Research	2009	470
Molecular Biomarker Analyses Using Circulating Tumor Cells Elizabeth A. Punnoose, Siminder Atwal, Jill M. Spoerke, PLoS ONE	2010	294
Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models Jie Lin, Deepak Sampath, Michelle Nannini, Clinical Cancer Research	2013	292
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant Jill M. Spoerke, Steven Gendreau, Kimberly Walter, Nature Communications	2016	292
Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models Carol O’Brien, Jeffrey J. Wallin, Deepak Sampath, Clinical Cancer Research	2010	257
Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors Dejan Juric, Ian E. Krop, Ramesh K. Ramanathan, Cancer Discovery	2017	159
Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy Michail Ignatiadis, Gert Van den Eynden, Roberto Salgado, JNCI Journal of the National Cancer Institute	2018	89
Molecular predictors of response to a humanized anti–insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer Jiping Zha, Carol O’Brien, Heidi Savage, Molecular Cancer Therapeutics Breast OncologyHuman GrowthIgf-ir ExpressionImmunologyEstrogen Receptor	2009	86
Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays Zachary Boyd, Qun Wu, Carol O’Brien, Molecular Cancer Therapeutics Breast OncologyEngineeringKinase InhibitorsReverse-phase ProteinSignaling Pathway	2008	69
Abstract S2-02: The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer – Part I results Ian E. Krop, Stephen Johnston, Ingrid A. Mayer, Cancer Research Breast OncologyPi3k Inhibitor PictilisibGynecologyPathologyAbstract S2-02	2015	60

Page 1